68.16USD-0.09%Mkt Cap: —P/E: 317.021d ago
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value16.52B $
Revenue (TTM)3.41B $
Gross Profit1.74B $
Net Income (TTM)72.97M $
Revenue/Share17.69 USD
Last Price68.16 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3.2K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS09061G1013
Valuation
P/E (Trailing)317.02
P/E (Forward)—
PEG—
EV/EBITDA25.59
EV/Revenue4.85
P/S—
P/B2.06
EPS (TTM)0.21
EPS (Forward)—
52W Range
66.6445% of range70.00
52W High70.00 USD
52W Low66.64 USD
Profitability
Gross Margin50.97%
Oper. Margin21.16%
EBITDA Margin18.94%
Profit Margin2.14%
ROE1.18%
ROA3.26%
Growth
Revenue Growth19.90%
Earnings Growth-81.30%
Cash Flow & Leverage
Operating CF857.09M $
CapEx (TTM)—
FCF Margin2.50%
FCF Yield—
Net Debt3.33B $
Net Debt/EBITDA5.16
Balance Sheet
Debt/Equity66.47
Current Ratio2.39
Quick Ratio1.16
Book Value/Sh32.66 USD
Cash/Share4.515 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.178.06M
Float192.39M
Insiders0.34%
Institutions103.70%
Technical
SMA 5090.32 (-24.5%)
SMA 20089.61 (-23.9%)
Beta0.23
S&P 52W Chg20.80%
Avg Vol (30d)933
Avg Vol (10d)10.44K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—